Why Is UNIQURE N V (QURE) Stock Up Today?

QURE stock rose 9.30% to $40.07 on Monday, driven by upgraded analyst sentiment and a regulatory update on its lead gene therapy candidate, AMT-130. The stock’s sharp rise followed a report that Wolfe Research upgraded the shares on an improved outlook for Huntington’s disease treatment, and a recent earnings call confirmed plans for a Biologics License Application (BLA) for AMT-130 in the third quarter of 2026. The company also extended its cash runway to 2030, reinforcing investor confidence in its ability to meet key milestones.

What Happened

Wolfe Research upgraded QURE stock, citing a positive trajectory for its Huntington’s disease therapy. The upgrade came alongside a Q2 2026 earnings call where the company detailed its plans for the AMT-130 BLA and confirmed that it has sufficient capital to fund operations through 2030. The call also highlighted progress in clinical programs for epilepsy and Fabry disease. The company filed an 8-K on July 29, disclosing its financial results and outlining regulatory submissions for AMT-130. While GAAP EPS of -$1.22 missed estimates by $0.42, revenue of $5.84 million beat expectations by $0.46 million, showing some operational resilience.

What The Data Shows

Over the last 8 sessions, the stock has declined 0.7% from $40.34 to $40.07, but the recent rally reversed that trend. Insiders have been active sellers in the past 90 days, with 20 transactions totaling $17.9 million. The CEO and Chief Medical Officer both sold shares in late June and early July. The stock currently trades within its 52-week range of $8.73 to $71.50, with a market cap of $2.6 billion. It remains unprofitable, with a trailing twelve-month (TTM) revenue decline of 10.4% and a TTM EPS of -3.49.

What To Watch

The company’s upcoming regulatory milestones for AMT-130 will be key to watch, particularly the BLA submission in Q3 2026. Investors should also monitor coverage breadth and analyst price targets as the stock continues to attract attention.